著者

千葉 薫 宮崎 勝巳 板谷 幸一 佐藤 誠二 高橋 保志 松原 和夫

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.28, no.1, pp.41-46, 2002-02-10 (Released:2011-03-04)

参考文献数

6

---

Hospital pharmaceutical preparations (HPP) are used in patients whose complications are not well controlled by the commercially available drugs or injections. The use of HPP is effective when HPP are proposed through clinical pharmacy services. A questionnaire was developed to evaluate the use of HPP and then was sent to 49 hospital pharmacies who belong to the Hokkaido Association for Hospital Pharmaceuticals.As a result, 32 institutions replied to questionnaire, thus indicating a recovery rate of 65%. HPP, including mixtures of injectable drugs, were used at 30 out of 32 institutions. According to the questionnaires, 11 hospitals manufactured 24 HPP which were used during clinical pharmacy services. Half of these preparations were used to care for adverse symptoms, such as stomatitis, induced by the cancer chemotherapy.The use of HPP prepared by clinical pharmacy services is closely related to patient's symptoms. The practical use of HPP is not only considered to improve drug compliance and the QOL of patients, but are also thought to enhance the general capabilities of pharmacists in clinical pharmaceutical practice.

著者

斉藤 嘉津彦 清水 瓊子 岡崎 正子 伊林 至洋 端 和夫 前野 康次郎 石井 清二 土橋 和文 島本 和明 戸田 貴大 黒澤 菜穂子 大和田 栄治 加藤 芳伸 大山 徹 梅津 有理 千田 道洋 有吉 範高 鎌滝 哲也 板谷 幸一

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.27, no.3, pp.228-234, 2001-06-10 (Released:2011-03-04)

参考文献数

11

被引用文献数

1 1

---

In recent years, genome science has undergone radical changes and numerous advances have led to the development of its use in medical practice. In particular developments in pharmacogenetics have demonstrated that genetic polymorphism is responsible for inter-individual differences in the drug metabolism. This study was conducted to identify the genetic polymorphisms of CYP 2C 9 and CYP 2 C19 using PCR-RFLP, and the application of a gene analysis was investigated in TDM or pharmaceutical management and in counseling services for patients. In a patient with the following pharmacokinetic parameters for phenytoin, for Km=6.69 μg/mL and Vmax = 3.62 mg/day/kg, and a largely decreased metabolic activity of CYP 2 C9 compared to the general population, the genetic differences in CYP 2 C9 could be determined in genomic DNA based on the patient's peripheral blood. Based on this finding, the effective dose for medication was calculated and administered to the patient. In addition, during medical consultations, both written and oral information in an easily comprehensible form could be given to patients with genetic polymorphism. These procedures allow a for the careful matching of the patient to the right medication and dose. This study indicates the possible application of a genetic analysis of CYP to “Evidence-Based Medicine” in the field of pharmaceutical management in order to control the dosage in individuals and to improve patient counseling.